Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid TumorsJoachim Drevs, Clemens Unger, Patrizia Siegert et al.|Journal of Clinical Oncology|2007Cited by 303
Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated DailyJoseph P. Eder, Donald Küfe, Milos J. Janicek et al.|Journal of Clinical Oncology|2002Cited by 244
Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials GroupScott A. Laurie, Lesley Seymour, Isabelle Gauthier et al.|Journal of Clinical Oncology|2008Cited by 120
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumoursHester van Cruijsen, Giuseppe Giaccone, Emile E. Voest et al.|European Journal of Cancer|2010Cited by 54
A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid MalignanciesJoseph P. Eder, Patricia LoRusso, Rocio García‐Carbonero et al.|Investigational New Drugs|2004Cited by 32